Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurol Sci ; 461: 123047, 2024 Jun 15.
Article in English | MEDLINE | ID: mdl-38759248

ABSTRACT

BACKGROUND: Myasthenia gravis (MG) with MuSK antibodies (MuSK-MG) represents a distinct subtype with different responses to treatments compared to patients with AChR antibodies, especially in terms of tolerance to acetylcholinesterase inhibitors (AChEI). However, AChEI are often used as first line symptomatic treatment in MuSK-MG, despite reports that they are poorly tolerated, seldom effective or even deleterious. METHODS: We analyzed demographic, clinical and therapeutic responses and side-effects in the large cohort of 202 MuSK-MG patients cared for at the MG Clinic of Azienda Ospedaliero-Universitaria Pisana. RESULTS: 165 patients had received AChEI at first evaluation. Only 7/165 patients (4.2%) reported an initial clinical benefit. Conversely, 76.9% of patients reported at least one side effect, most commonly neuromuscular hyperexcitability (68.4%), gastrointestinal (53.9%) and neurovegetative (35.8%) disturbances. 56 (33.9%) patients reported a concomitant worsening of muscle weakness and twelve patients (7.3%) suffered a cholinergic crisis. According to these patients, the severity of cholinergic side effects was greater at higher doses of AChEI, but side effects occurred regardless of the dose administered and ceased once the drug was discontinued. CONCLUSIONS: This is the largest population of MuSK-MG patients reported for perceived responsiveness and tolerance to AChEI treatment. Our obervations strongly suggest avoiding this treatment in MuSK-MG.


Subject(s)
Autoantibodies , Cholinesterase Inhibitors , Myasthenia Gravis , Receptor Protein-Tyrosine Kinases , Receptors, Cholinergic , Humans , Myasthenia Gravis/drug therapy , Myasthenia Gravis/immunology , Cholinesterase Inhibitors/therapeutic use , Male , Female , Middle Aged , Receptors, Cholinergic/immunology , Adult , Receptor Protein-Tyrosine Kinases/immunology , Receptor Protein-Tyrosine Kinases/antagonists & inhibitors , Aged , Autoantibodies/blood , Young Adult , Adolescent , Aged, 80 and over , Treatment Outcome , Cohort Studies
2.
Lymphology ; 56(1): 13-26, 2023.
Article in English | MEDLINE | ID: mdl-38019876

ABSTRACT

The aim of this pilot study was to investigate the effects of defocused and radial shock wave therapy, mesotherapy, and kinesio taping on pain, circumferences of lower limbs, echographic/ elastosonographic pattern of subcutaneous adipose tissue (SAT), and quality of life in patients with lipedema. Fifteen women affected by lower limb lipedema in stage II were treated with shock wave therapy, mesotherapy, and kinesio taping on thighs and legs (eight sessions, twice a week). The primary outcome was pain, as assessed by Numeric Rating Scale (NRS). Secondary outcomes included the limb circumferences measurements, the SF-12 Health Survey for quality of life, the International Classification of Functioning (ICF) for disability, and echographic/ elastosonographic changes of SAT. Significant reductions of pain and circumference measurements were seen in patients at each follow up. This was associated with significant reduction of thickness, echographic pattern improvement, and increased elasticity of SAT, with consequent positive impact on the quality of life and disability reported by the patients. The results demonstrate improved clinical and functional ultrasound findings in patients affected by lipedema in the early stages of lower limbs, and this combination therapy needs to be investigated in larger populations at multiple centers to confirm the findings.


Subject(s)
Extracorporeal Shockwave Therapy , Lipedema , Mesotherapy , Humans , Female , Lipedema/therapy , Pilot Projects , Quality of Life , Pain
3.
Crit Care Nurs Q ; 19(1): 83-7, 1996 May.
Article in English | MEDLINE | ID: mdl-8705703

ABSTRACT

Continuous performance improvement in care a patient receives is of paramount importance to Robert Packer Hospital, a regional, accredited trauma center in rural Pennsylvania. In fall 1991, a care delivery system known as case management was introduced as a mode for achieving this continuous performance improvement goal. The staff members' experience with the initial development and use of a trauma critical pathway was first published in the November 1993 issue of Critical Care Nursing Quarterly. Now, 3 years later, case management has proven to be a viable means to accomplish the continuous performance improvement goal by enhancing the quality of care for trauma patients and their families throughout hospitalization. This article reviews the outcomes over the past 3 years as a result of case management and the use of trauma critical pathways.


Subject(s)
Case Management/organization & administration , Critical Pathways , Multiple Trauma/nursing , Total Quality Management/organization & administration , Humans , Program Evaluation
SELECTION OF CITATIONS
SEARCH DETAIL
...